US006962785B2

(12) **United States Patent**
Agris et al.

(10) **Patent No.:** **US 6,962,785 B2**
(45) **Date of Patent:** **Nov. 8, 2005**

(54) **ANTIBACTERIAL AND ANTIVIRAL AGENTS AND METHODS OF SCREENING FOR THE SAME**

(75) Inventors: **Paul F. Agris**, Raleigh, NC (US); **Salman Ashraf**, Raleigh, NC (US)

(73) Assignee: **North Carolina State University**, Raleigh, NC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 132 days.

(21) Appl. No.: **10/212,905**

(22) Filed: **Aug. 6, 2002**

(65) **Prior Publication Data**

US 2003/0008808 A1 Jan. 9, 2003

Related U.S. Application Data

(63) Continuation of application No. 09/315,674, filed on May 20, 1999, now Pat. No. 6,461,815.
(60) Provisional application No. 60/086,380, filed on May 22, 1998.

(51) **Int. Cl.**[7] **C12Q 1/68**; C07H 21/02; C07H 21/04
(52) **U.S. Cl.** **435/6**; 536/23.1; 536/24.1
(58) **Field of Search** 435/236, 4; 436/6; 536/23.1, 24.1

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,358,862	A	10/1994	Hardesty et al.	
5,556,840	A	9/1996	Suhadolnik et al.	514/44
5,629,188	A	5/1997	Shiba et al.	
5,674,729	A	10/1997	Wimmer et al.	435/235.1
5,712,096	A	1/1998	Stern et al.	
5,821,052	A	10/1998	Chen et al.	

FOREIGN PATENT DOCUMENTS

ES	2040615	5/1991	C12N/7/02
JP	60-196197	10/1985	C12P/21/02

OTHER PUBLICATIONS

Crooke, S.T., Antisense Research and Application , Chapter 1, Springer–verlag, (New York. 1998).*
Branch A.D . . . TIBS. vol. 23. p. 45–50 (Feb. 1998).*
Stein. C.A . . . Nature Biotechnology vol. 17. pp. 751–752 (Aug. 1999).*
Flanagan. W.M.S et al . . . Nature Biotechnologv. vol. 17 p. 48–52 (Jan. 1999).*
Lloyd. A.W. DDT, vol. 2. No. 10 (Oct. 1997).*
Goodman. M . . . DDT, vol. 2. No. 9. (Sep. 1997).*
Wess, G., DDT vol. 1. No. 12 (Dec. 1996).*
Dirani–Diab et al., Antimicrobial Agents and Chemotherapy, 1997, vol. 41, p 2141–2148.*
Sarih–Cotton et al., "Preferential interaction of HIV reverse transcriptase with two regions of primer tRNALys as evidenced by footprinting studies and inhibition with synthetic oligoribonucleotides", Journal of Molecular Biology, 1992, vol. 226, p. 1–6.*

Agris, et al., *Unique Structure Explains Human tRNA(Lys3) Selection by HIV Reverse Transcriptase, Presented at the RNA Society 1996 Meeting* (Feb. 15, 1996).

Agris, et al., *Unique Structure Explains Unusual Biochemical Properties of tRNA(Lys)SUU, Presented at the ASBMB 1996 Meeting* (Jan. 30, 1996).

Ashraf, S. Salman, et al., *Single atom modification (O–>S) of tRNA confers ribosome binding, RNA*, vol. 5, pp. 188–194 (1999).

Baldwin, John J., et al., *Recent Advances in the Generation of Small–Molecule Combinatorial Libraries: Encoded Split Synthesis and Solid–Phase Synthetic Methodology, Medicinal Research Reviews*, vol. 16, No. 5, pp. 391–405 (1996).

Brierley, Ian, et al., *Expression of a Coronavirus Ribosomal Frameshift Signal in Escherichia coli: Influence of tRNA Anticodon Modification on Frameshifting, J. Mol Biol.*, vol. 270, pp. 360–373 (1997).

Guenther, et al., *Modified RNAs as potential drug targets, Acta Biochimica Polonica*, vol. 45, No. 1, pp. 13–18 (1998).

Heurgué–Hamard, Valérie, et al., *The growth defenct in Escherichia coli deficient in peptidyl–tRNA hydrolase is due to starvation for Lys–tRNA^{Lys}, EMBO Journal*, vol. 15, No. 11, pp. 2826–2833 (1996).

Kumar, Raju K., et al., *Synthesis and studies on the effect of 2–thiouridine and 4–thiouridine on sugar conformation and RNA duplex stability, Nucleic Acids Research*, vol. 25, No. 6, pp. 1272–1280 (1997).

McClain, William H., et al., *Nucleotides that determine Escherichia coli tRNA^{Arg} and tRNA^{Lys} acceptor identities revealed by analyses of mutant opal and amber suppressor tRNAs, Proc. Natl. Acad. Sci. USA*, vol. 87, pp. 9260–9264 (Dec. 1990).

Penner, Michael, et al., *Phase T4–coded Stp: Double–Edged Effector of Coupled DNA and tRNA–Restriction Systems, J Mol. Biol.*, vol. 249, pp. 857–868 (1995).

Sprinzl, Mathias, et al., *Compilation of tRNA sequences and sequences of tRNA genes, Nucleic Acids Research*, vol. 26, No. 1, pp. 148–153 (1998).

(Continued)

Primary Examiner—Andrew Wang
Assistant Examiner—Tracy Vivlemore
(74) *Attorney, Agent, or Firm*—Myers Bigel Sibley & Sajovec, P.A.

(57) **ABSTRACT**

A method of screening for compounds useful for inhibiting retrovirus propagation in a host for the retrovirus, wherein the retrovirus primes reverse transcription in the host by binding of a specific host tRNA to retrovirus RNA at at least a pair of separate binding sites on the host tRNA, comprises contacting the specific host tRNA to the retrovirus RNA in the presence of the test compound, and then determining whether the compound inhibits the binding of the specific host tRNA to the retrovirus RNA in the presence of the test compound.

5 Claims, 6 Drawing Sheets